Bladder cancer is among the top 10 most common cancer types in the world, with approximately 573,000 new cases annually. Men ...

UroGen Pharma ( NASDAQ: URGN) announced on Wednesday that the U.S. FDA has scheduled an Oncologic Drugs Advisory Committee ...

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment ...

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company ...

Congressman Greg Murphy, M.D., is recognizing May as Bladder Cancer Awareness Month. “While most bladder cancers are caught ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

Though the connection seems unusual, this news could change the lives of more than 700,000 Americans living with this disease ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder ...

Chris Cotton is raising money for cancer centers after being told the day after his 50th birthday that what he thought was a ...

What are the signs and symptoms of bladder cancer, and what are its risk factors? Here's what you need to know, according to an expert.

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.